GSK (NYSE:GSK) Shares Up 3.5% – Should You Buy?

Shares of GSK PLC Sponsored ADR (NYSE:GSK) traded up 3.5% during mid-day trading on Wednesday. The company traded as high as $47.87 and last traded at $47.8950. Approximately 3,048,071 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 4,460,884 shares. The stock had previously closed at $46.27.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK and Oxford University dosed the first patient in a clinical trial evaluating a potential treatment for ulcerative colitis. The program expands GSK’s immunology pipeline, although the trial is at an early stage and offers no near-term revenue impact. First Patient Dosed in GSK-Oxford Colitis Trial
• Positive Sentiment: GSK plans to invest approximately $800 million to demolish and rebuild its Upper Merion, Pennsylvania, facility. The expansion should strengthen U.S. manufacturing capacity and may support the company’s long-term supply and operational strategy. GSK to invest $800M in Pennsylvania expansion
• Neutral Sentiment: RBC expects GSK’s third-quarter results to be broadly in line with expectations. Strength in HIV medicines and respiratory treatment Nucala is expected to offset weaker vaccine sales; RBC maintained its Sector Perform rating and 1,975p price target ahead of the October 28 earnings release. GSK third quarter outlook from RBC
• Negative Sentiment: GSK is reportedly planning to eliminate up to 1,217 jobs in Belgium, primarily affecting its vaccine operations. The cuts could eventually reduce costs, but the scale of the restructuring raises concerns about near-term disruption and reflects pressure on vaccine demand. GSK to cut up to 1,217 jobs in Belgium

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Sanford C. Bernstein reaffirmed a “buy” rating on shares of GSK in a report on Sunday, August 2nd. Royal Bank Of Canada started coverage on GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. The Goldman Sachs Group reaffirmed a “neutral” rating on shares of GSK in a research report on Monday, June 29th. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of GSK in a report on Thursday, October 1st. Finally, Wolfe Research began coverage on GSK in a research report on Friday, October 9th. They set an “outperform” rating and a $70.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $55.33.

GSK Price Performance

The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The company has a 50-day moving average of $49.82 and a 200-day moving average of $51.73. The stock has a market cap of $96.82 billion, a price-to-earnings ratio of 14.96, a PEG ratio of 2.11 and a beta of 0.33.

GSK (NYSE:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. GSK’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities research analysts predict that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were given a $0.4515 dividend. The ex-dividend date was Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 annualized dividend and a yield of 3.8%. GSK’s dividend payout ratio (DPR) is currently 55.31%.

Institutional Investors Weigh In On GSK

Several institutional investors have recently modified their holdings of the company. Focus Financial Network Inc. boosted its position in shares of GSK by 10.4% in the 3rd quarter. Focus Financial Network Inc. now owns 4,345 shares of the pharmaceutical company’s stock worth $209,000 after buying an additional 410 shares in the last quarter. Roberts Wealth Advisors LLC increased its position in GSK by 2.3% during the 3rd quarter. Roberts Wealth Advisors LLC now owns 87,733 shares of the pharmaceutical company’s stock worth $4,226,000 after purchasing an additional 2,014 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its stake in GSK by 4.3% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 8,485 shares of the pharmaceutical company’s stock valued at $409,000 after purchasing an additional 352 shares during the last quarter. Sax Wealth Advisors LLC acquired a new position in GSK in the 3rd quarter valued at about $394,000. Finally, HF Advisory Group LLC lifted its holdings in GSK by 6.7% in the 3rd quarter. HF Advisory Group LLC now owns 8,084 shares of the pharmaceutical company’s stock valued at $389,000 after purchasing an additional 506 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.